63 - Statistical Considerations in Phase 3 (S5E3)

This episode takes a deep dive into the advanced statistical methods employed in Phase 3 clinical trials, examining the concepts of statistical power and significance. We explore the factors that determine a trial's power, including sample size, treatment effect size, and data variability, and how these factors are intertwined in the sample size calculation process. We discuss the role of randomization and how it helps to minimize bias by ensuring balanced treatment groups. The concept of the significance threshold and its role in determining if the observed treatment effects are real or just due to chance is also explored. Join us as we unpack the statistical framework that underpins the analysis and interpretation of data in these pivotal trials.

We further explore the intricacies of data analysis in Phase 3 trials, discussing various statistical techniques used to analyze different types of data, such as t-tests for comparing means and Kaplan-Meier curves and Cox proportional hazard models for time-to-event outcomes. The concept of non-inferiority trials and how they differ from superiority trials in terms of their objectives and statistical analysis is also explained. We also delve into the importance of confidence intervals in providing a range of plausible values for the true treatment effect and how they contribute to a more nuanced interpretation of results. Finally, we discuss the challenges of multiple testing and missing data and how statisticians address these challenges to ensure the reliability of trial findings. Tune in to gain a deeper understanding of the statistical tools and techniques used to evaluate the effectiveness and safety of new drugs in Phase 3 trials.